Innohep (Tinzaparin Sodium)

Tinzaparin sodium enhances antithrombin III activity, which accelerates the inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin). This reduces thrombin generation and fibrin clot formation, providing an anticoagulant effect that helps prevent and treat venous thromboembolic events.

The specific dose of Innohep is individualized and must be determined by a qualified prescriber based on the patient’s clinical condition, weight, renal function, and indication. Healthcare professionals calculate the appropriate regimen and monitor therapeutic response.

Safety data for tinzaparin sodium in pregnancy and lactation are limited. The product should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by the treating physician.

To order Innohep, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Compared with unfractionated heparin, tinzaparin offers more predictable pharmacokinetics, a lower risk of heparin‑induced thrombocytopenia, and once‑daily dosing for many indications. Relative to other low molecular weight heparins, its anti‑Xa activity is similar, but dosing and monitoring requirements may differ, so clinicians choose based on patient profile and therapeutic goals.

Innohep should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Do not use the product if it has been exposed to temperatures outside the recommended range.

Innohep is administered by a healthcare professional via subcutaneous injection, and in some clinical settings it may be given intravenously. The injection site is typically the abdomen or thigh, and proper aseptic technique must be followed to minimize local reactions.

The most serious risks include major bleeding (such as intracranial or gastrointestinal hemorrhage), heparin‑induced thrombocytopenia (HIT), and spinal or epidural hematoma, especially after neuraxial procedures. Prompt recognition and medical intervention are essential if these events occur.

Innohep is contraindicated in patients with active major bleeding, known hypersensitivity to tinzaparin or any heparin product, and those with a history of heparin‑induced thrombocytopenia. Caution is also advised for patients with severe renal impairment, uncontrolled hypertension, or recent major surgery.